These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 28145643)
1. Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers. Lee HY; Lee SH; Won JK; Lee DS; Kwon NJ; Choi SM; Lee J; Lee CH; Lee SM; Yim JJ; Yoo CG; Kim YW; Han SK; Park YS J Korean Med Sci; 2017 Mar; 32(3):415-420. PubMed ID: 28145643 [TBL] [Abstract][Full Text] [Related]
2. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644 [TBL] [Abstract][Full Text] [Related]
3. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997 [TBL] [Abstract][Full Text] [Related]
4. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2). Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650 [TBL] [Abstract][Full Text] [Related]
5. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Jin G; Kim MJ; Jeon HS; Choi JE; Kim DS; Lee EB; Cha SI; Yoon GS; Kim CH; Jung TH; Park JY Lung Cancer; 2010 Sep; 69(3):279-83. PubMed ID: 20018398 [TBL] [Abstract][Full Text] [Related]
6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301 [TBL] [Abstract][Full Text] [Related]
7. Small-cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Sun JM; Choi YL; Ji JH; Ahn JS; Kim KM; Han J; Ahn MJ; Park K Ann Oncol; 2015 Jan; 26(1):161-166. PubMed ID: 25355724 [TBL] [Abstract][Full Text] [Related]
8. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma. Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652 [TBL] [Abstract][Full Text] [Related]
9. Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. Kim HR; Cho BC; Shim HS; Lim SM; Kim SK; Chang J; Kim DJ; Kim JH Lung Cancer; 2014 Mar; 83(3):374-82. PubMed ID: 24468202 [TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250 [TBL] [Abstract][Full Text] [Related]
11. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma. Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303 [TBL] [Abstract][Full Text] [Related]
12. Clinical and genetic features of lung squamous cell cancer in never-smokers. Huang Y; Wang R; Pan Y; Zhang Y; Li H; Cheng C; Zheng D; Zheng S; Li Y; Shen X; Hu H; Cai D; Wang S; Zhang Y; Xiang J; Sun Y; Zhang J; Chen H Oncotarget; 2016 Jun; 7(24):35979-35988. PubMed ID: 27092882 [TBL] [Abstract][Full Text] [Related]
13. The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. Kim YT; Seong YW; Jung YJ; Jeon YK; Park IK; Kang CH; Kim JH J Thorac Oncol; 2013 Feb; 8(2):171-8. PubMed ID: 23287850 [TBL] [Abstract][Full Text] [Related]
14. Genetic mutation screen in early non--small-cell lung cancer (NSCLC) specimens. Bar J; Damianovich M; Hout Siloni G; Dar E; Cohen Y; Perelman M; Ben Nun A; Simansky D; Yellin A; Urban D; Onn A Clin Lung Cancer; 2014 Mar; 15(2):159-65. PubMed ID: 24370118 [TBL] [Abstract][Full Text] [Related]
15. Specificities of lung adenocarcinoma in women who have never smoked. Mazières J; Rouquette I; Lepage B; Milia J; Brouchet L; Guibert N; Beau-Faller M; Validire P; Hofman P; Fouret P J Thorac Oncol; 2013 Jul; 8(7):923-9. PubMed ID: 23608817 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. Scoccianti C; Vesin A; Martel G; Olivier M; Brambilla E; Timsit JF; Tavecchio L; Brambilla C; Field JK; Hainaut P; Eur Respir J; 2012 Jul; 40(1):177-84. PubMed ID: 22267755 [TBL] [Abstract][Full Text] [Related]
17. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing. He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796 [TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure. Arrieta O; Campos-Parra AD; Zuloaga C; Avilés A; Sánchez-Reyes R; Manríquez ME; Covián-Molina E; Martínez-Barrera L; Meneses A; Cardona A; Borbolla-Escoboza JR J Thorac Oncol; 2012 Aug; 7(8):1228-34. PubMed ID: 22659961 [TBL] [Abstract][Full Text] [Related]
19. p53 mutations and exposure to environmental tobacco smoke in a multicenter study on lung cancer. Husgafvel-Pursiainen K; Boffetta P; Kannio A; Nyberg F; Pershagen G; Mukeria A; Constantinescu V; Fortes C; Benhamou S Cancer Res; 2000 Jun; 60(11):2906-11. PubMed ID: 10850436 [TBL] [Abstract][Full Text] [Related]
20. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. Choi H; Kratz J; Pham P; Lee S; Ray R; Kwon YW; Mao JH; Kang HC; Jablons D; Kim IJ Int J Oncol; 2012 Jun; 40(6):1900-6. PubMed ID: 22407457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]